Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
Opinion|Videos|April 13, 2026
Updated Efficacy and Safety Results of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the Ongoing Phase 1 CaDAnCe-101 Study
Author(s)Nicole Lamanna, MD
UCSF real-world CLL study pits zanubrutinib vs acalabrutinib, showing fewer next treatments and AI-extracted adverse events.
Advertisement
This presentation reports updated results on a novel BTK degrader therapy for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The treatment showed strong anti-tumor activity across different patient subgroups, including those with prior therapies and resistance mutations, while maintaining a manageable safety profile without new concerns about toxicities. Overall, the findings suggest this therapy is a promising option that continues to be evaluated in ongoing clinical studies.
Advertisement
Related to this article
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
The FDA granted final approval to aLutetium Lu 177 dotatate biosimilar for patients with SSTR-positive GEP-NETs.
The TrueBeam photon therapy system has been added to the Statesir Cancer Center at Atlantic Health CentraState Medical Center.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
Updated NCCN guidelines now recommend rusfertide as a Category 1 option for both low- and high-risk polycythemia vera.
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
2
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
3
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5